Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes

Efficacy and Safety of Retagliptin Phosphate in Combination With Metformin in Type 2 Diabetic Subjects With Poor Metformin Glycemic Control: a Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Design

Retagliptin phosphate tablet is a DPP IV inhibitor durg，study number is HR-SP2086-304. The primary purpose of the study is to evaluate the efficacy of the combination of Retagliptin phosphate and metformin compared with placebo and metformin in type 2 diabetes subjects with poor glycemic control treated with metformin for 16 weeks.

Study Overview

• Status: Active, not recruiting
• Conditions: Type 2 Diabetes
• Intervention / Treatment: Drug: Retagliptin phosphate tablets、metformin sustained-release tablets; Drug: Retagliptin phosphate placebo tablets、metformin sustained-release tablets

• Study Type: Interventional
• Enrollment (Actual): 174
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100000
      • Beijing Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Voluntarily signed the informed consent, understood the procedures and methods of the study, and was willing to complete the study strictly in accordance with the clinical trial protocol;
2. The screening age should be 18-75 years old (including both ends), male or female;
3. Diagnosed with type 2 diabetes, 7.5%≤HbA1c≤11%;
4. At least 8 weeks prior to screening, in addition to regular diet control and exercise, a steady dose of metformin ≥1500mg/d;
5. Fasting glucose ≤13.3mmol/L; 6、19.0 < BMI 35.0 kg/m2 or less.

Exclusion Criteria:

1. General situation:

   • 1) Known or suspected allergy to DPP4i drugs or investigational drug excipients;
   • 2) Pregnant or lactating women, fertile men or women were unwilling to use contraception during the study period;

2. History or evidence of any of the following diseases at the time of screening:

   • 1) Type 1 diabetes, single-gene mutation diabetes, diabetes due to pancreatic damage, or other secondary diabetes (e.g., diabetes due to Cushing's syndrome or acromegaly);
   • 2) Acute metabolic complications (such as ketoacidosis, lactic acidosis or hypertonic coma) occurred within 6 months prior to screening; Or have serious chronic complications of diabetes in the past (such as severe macrovascular or microvascular complications as judged by the investigator) and the investigator considers that they are not suitable to participate in this study;
   • 3) There is a history of severe hypoglycemia (such as drowsiness, disturbance of consciousness, delirium, or even coma caused by hypoglycemia, which requires the assistance of others for treatment), or repeated hypoglycemia (≥3 symptomatic hypoglycemia within a week, or blood glucose <3.0 mmol/L detected at least 3 times within a week);
   • 4) Patients with poorly controlled hypertension at screening were defined as systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg;
   • 5) Had myocardial infarction, unstable angina, stroke (except lacunar infarction without attack symptoms) or transient ischemic attack, or had undergone coronary angioplasty, percutaneous coronary stent implantation or coronary artery bypass grafting within 6 months prior to screening; Or had congestive heart failure (NYHA grades III and IV), unstable or acute congestive heart failure, or persistent arrhythmias that the investigator determined significantly affected the subjects' safety within the 6 months prior to screening;
   • 6) History of acute and chronic pancreatitis, or risk factors that may lead to pancreatitis, such as history of symptomatic gallbladder, history of pancreatic injury, etc. (except cholecystectomy);
   • 7) A history of malignant tumor within 5 years prior to screening, excluding treated local basal cell carcinoma of the skin;
   • 8) have obvious diseases of the blood system (such as aplastic anemia, myelodysplastic syndrome, hemolytic anemia) or any diseases causing hemolysis or red blood cell instability (such as malaria);
   • 9) Clinically significant gastric emptying abnormalities (e.g., gastric outlet obstruction), severe chronic gastrointestinal diseases (e.g., active ulcers within 6 months prior to screening);
   • 10) There is a history of drug or alcohol abuse within 3 months prior to screening, which may affect the subject's compliance to participate in the test according to the investigator's judgment;

3. Received any of the following pharmacological or non-pharmacological treatments or procedures prior to screening:

   • 1) Any hypoglycemic drug treatment other than metformin within 2 months prior to screening, including Chinese herbal therapy for hypoglycemic purposes (except cumulative use ≤7 days);
   • 2) received systemic steroid hormone therapy (including intravenous and oral administration) and intraarticular administration for more than 7 days within 2 months prior to screening;
   • 3) Bariatric surgery or procedures (e.g. gastric banding surgery) within 12 months prior to screening, or use of weight-loss medications within 3 months prior to screening, or weight fluctuation ≥10% within 3 months prior to screening;
   • 4) Have received other gastrointestinal surgery that may lead to malabsorption before screening, or long-term use of drugs that directly affect gastrointestinal motility;
   • 5) Have received blood transfusion, blood donation or blood loss ≥400 mL within 3 months before screening;
   • 6) Participated in clinical trials of any drug or medical device within 3 months prior to screening (subject to entering into randomised procedures);

4. Any of the laboratory test indicators during screening meet the following standards (those who meet the criteria can be retested once within one week if there is a clear reason for retesting) :

   • 1) Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥3.0×ULN and/or total bilirubin ≥2.0×ULN;
   • 2) patients with renal function injury were defined as eGFR <60ml/min/1.73 m2 (calculated according to the simplified formula of dietary adjustment for renal disease (MDRD));
   • 3) Thyroid function test: abnormal thyroid stimulating hormone (TSH), serum free triiodothyronine (FT3), serum free thyroxine (FT4);
   • 4) Fasting triglyceride ≥5.64 mmol/L (500 mg/ dL);
   • 5) Blood amylase or lipase exceeded the upper limit of the normal range and was clinically significant as judged by researchers
5. Significant abnormal 12-lead electrocardiogram (ECG) results during screening, which the investigator considered might affect the safety of the subjects and are not suitable for this study;
6. Any other conditions (such as affecting the safety or efficacy evaluation of the subjects) that the investigator deemed inappropriate for the subjects to participate in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: treatment group A	Drug: Retagliptin phosphate tablets、metformin sustained-release tablets; Retagliptin phosphate tablets 100mg+ metformin sustained-release tablets 1500mg or 2000mg based on prior medication
Placebo Comparator: treatment group B	Drug: Retagliptin phosphate placebo tablets、metformin sustained-release tablets; Retagliptin phosphate 100mg placebo tablets + metformin sustained-release tablets 1500mg or 2000mg based on prior medication

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Changes in HbA1c relative to baseline	After 16 weeks of treatment

Secondary Outcome Measures

Outcome Measure	Time Frame
The proportion of subjects with HbA1c<6.5% and HbA1c< 7% after 16 weeks of treatment	up to 16 weeks of treatment
Changes in fasting plasma glucose relative to baseline	up to 16 weeks of treatment
Changes in 2h postprandial blood glucose relative to baseline	up to 16 weeks of treatment
Changes in body weight relative to baseline	up to 16 weeks of treatment
Percentage of subjects in each group who received remedial treatment	up to 16 weeks of treatment]
The incidence of adverse events of SP2086	From Day 1 to Day 113
The incidence of Hypoglycemic event of SP2086	From Day 1 to Day 113
Evaluate the concentrations of SP2086 in Type 2 diabetes	up to 16 weeks of treatment
Evaluate the concentration of the main metabolite of SP2086 in Type 2 diabetes	up to 16 weeks of treatment

Collaborators and Investigators

• Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): December 6, 2021
• Primary Completion (Estimated): December 1, 2023
• Study Completion (Estimated): December 1, 2023

Study Registration Dates

• First Submitted: September 9, 2021
• First Submitted That Met QC Criteria: September 17, 2021
• First Posted (Actual): September 23, 2021

Study Record Updates

• Last Update Posted (Actual): July 10, 2023
• Last Update Submitted That Met QC Criteria: July 7, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Metformin
• Other Study ID Numbers: HR-SP2086-304

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No